NCT05087342

Latino Semaglutide Study

A Randomized Latino Semaglutide 2.4mg Study

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 119 (actual)
• Sponsor: Loma Linda University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study to understand better how this anti-obesity medication works to assist individuals to lose weight and maintain weight loss. This study may lead to the development of other related medications for assisting people with the disease of obesity.

Conditions

• Obesity
• Obesity; Drug
• Overweight or Obesity
• Weight Loss
• Weight Loss Trajectory
• Weight, Body

Interventions

Type	Name	Description
DRUG	Semaglutide 2.4mg	The intervention drug, semaglutide 2.4mg will be given to the Intervention Group per the schedule outlined in the armed description.
DRUG	Placebo	A placebo will be given to the control group per the schedule outlined in the armed description.

Timeline

• Start date: 2022-12-13
• Primary completion: 2024-05-29
• Completion: 2024-05-29
• First posted: 2021-10-21
• Last updated: 2024-10-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study